Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Biomarker in Lung Diseases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Heidelberg University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
NCT00989846
First received: October 5, 2009
Last updated: October 13, 2009
Last verified: October 2009
  Purpose

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results


Condition Intervention
Lung Diseases
Other: biomarker

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Feasibility Study on Establishing Biomarkers in Lung Diseases

Further study details as provided by Heidelberg University:

Primary Outcome Measures:
  • Serum biomarker expression [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum (blood)


Estimated Enrollment: 120
Study Start Date: October 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
lung disease
patients with various chronic or acute lung diseases
Other: biomarker
measuring serum-biomarkers

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with acute or chronic lung diseases

Criteria

Inclusion Criteria:

  • age >= 18
  • acute or chronic lung disease

Exclusion Criteria:

  • HIV
  • lactation or gestation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00989846

Contacts
Contact: Michael Kreuter, MD 49 / 6221 / 396 ext 1201 michael.kreuter@thoraxklinik-heidelberg.de

Locations
Germany
Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care Recruiting
Heidelberg, Germany, 69126
Contact: Michael Kreuter, MD    49 / 6221 / 396 ext 1201    michael.kreuter@thoraxklinik-heidelberg.de   
Principal Investigator: Michael Kreuter, MD         
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Michael Kreuter, MD Thoraxklinik Heidelberg, Germany
Study Director: Felix JF Herth, MD Thoraxklinik Heidelberg Germany
  More Information

Publications:
Responsible Party: Dr. Michael Kreuter, Thoraxklinik Heidelberg
ClinicalTrials.gov Identifier: NCT00989846     History of Changes
Other Study ID Numbers: MK02
Study First Received: October 5, 2009
Last Updated: October 13, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Heidelberg University:
biomarker
lung disease

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 19, 2014